Table 4.
Differences in adverse clinical health outcomes between TD (testosterone deficiency treatment in cisgender men) and GAHT (gender affirmation hormone treatment), N = 481.
| Outcome | Tested | Adverse outcomes, n (%) | aOR (95% CI) | p-value |
|---|---|---|---|---|
| 1. Polycythemia | ||||
| TD | 154 | 14 (9.1) | ref. | – |
| GAHT | 250 | 4 (1.6) | 0.21 (0.04–1.22) | 0.083 |
| 2. Hypertension | ||||
| TD | 203 | 50 (24.6) | ref. | – |
| GAHT | 250 | 17 (6.8) | 0.23 (0.08–0.66) | 0.006 |
| 3. Liver abnormalities | ||||
| TD | 209 | 56 (26.7) | ref. | – |
| GAHT | 277 | 51 (18.4) | 0.92 (0.41–2.07) | 0.837 |
| 4. Hypercholesterolemia | ||||
| TD | 174 | 47 (27.0) | ref. | – |
| GAHT | 185 | 48 (26.0) | 1.08 (0.44–2.67) | 0.860 |
OR: odds ratio; aOR: adjusted odds ratio; ref.: reference category.
Note: Adjusted models included age, BMI, HIV status and smoking status.